You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海普瑞(09989.HK)與正大天晴訂立分銷及供應協議

格隆匯4月3日丨海普瑞(09989.HK)公吿,於2023年3月30日,公司的全資子公司Techdow USA Inc.("天道美國")與正大天晴藥業集團股份有限公司("正大天晴")訂立分銷及供應協議,據此,正大天晴同意向天道美國授出福沙匹坦二葡甲胺(以下簡稱"標的藥品")在美國商業化的許可。

根據協議,天道美國將負責標的藥品在美國市場的商業化工作,包括營銷、推廣、銷售和分銷產品。同時,天道美國將向正大天晴以約定價格購買該標的藥品,並按照一定的比例與正大天晴共享標的藥品的銷售淨利潤。

福沙匹坦二葡甲胺(FosaprepitantDimeglutide)為一種神經激肽-1受體阻滯劑,用於預防及治療由高致吐化療(HEC)方案引起的噁心及嘔吐。國際指引普遍建議採用NK-1受體拮抗劑、5-HT3受體拮抗劑及地塞米松三聯方案作為一線止吐方案。

本次合作是集團結合公司發展戰略及市場調研後深思熟慮的成果。在美國市場,標的藥品的銷售模式和銷售渠道與標準肝素製劑全面重合,因此對於集團美國自營團隊而言,對標的藥品及公司肝素製劑的銷售具有高度的協同效應。公司可憑藉成熟的自營銷售網絡及渠道,在新增較低的銷售成本下對該標的藥品進行推廣、銷售。

天道美國本次與正大天晴根據協議進行戰略合作,是集團堅持國際化經營及助力中國藥企藥品出海歐美市場戰略的體現與探索。集團在歐洲五國、美國建立了完備的自營團隊,擁有成熟的自營銷售網絡及渠道。本次合作是市場對於集團在海外市場營銷能力的一次肯定,也是本公司探索海外市場營銷積累經驗的重要機會,對集團未來與其它醫藥企業的合作有深遠且積極的意義。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account